Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCT-810 phase 2 in adolescent and adult participants with ornithine transcarbamylase deficiency
2021-001081-38Phase 2Completed
- Sponsor
- Arcturus Therapeutics
- Start
- Aug 2021
- Modality
- Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ornithine transcarbamylase deficiency and urea cycle disorder (UCD) comparing ARCT-810 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Aug 2021; status: completed.
02
Drugs
ARCT-810
03
Conditions
ornithine transcarbamylase deficiencyurea cycle disorder (UCD)
Beyond the preview
Go deeper on 2021-001081-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001081-38.